Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead program, MZE829, a dual-mechanism APOL1 inhibitor developed as an oral therapy for APOL1-mediated kidney disease (AMKD), a condition that disproportionately affects people of African ancestry. MZE829 has advanced to a Phase 2 clinical trial, with topline proof-of-concept data expected by the end of the first quarter of 2026. The Phase 1 data demonstrated a favorable safety profile, dose-proportional pharmacokinetics, and minimal drug-drug interaction risk, supporting the selection of a 250 mg once-daily dose for Phase 2. Additional pipeline programs include MZE782 for phenylketonuria (PKU), which is Phase 2 ready with trial initiation planned for mid-2026, and a chronic kidney disease program set to begin Phase 2 in the second half of 2026. The company reports an expected cash runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.